Edesa Biotech, Inc. (EDSA) stock
EDSANasdaqPharmaceutical PreparationsFiscal year ends September 30
$2.06+0.10 (+5.10%)
Close on Nov 18, 2026Market cap $19.86MP/E –Yield –
Edesa Biotech revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Edesa Biotech's revenue for the twelve months ending Sep 30, 2021 was $0, down 100.0% year over year. For fiscal 2021 it was $0, down 100.0% from the year before. The highest annual figure on record is $1.27M in fiscal 2016.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Sep 30, 2021 | $0 | -100.0% |
| FY2020 | Sep 30, 2020 | $328.80K | +55.2% |
| FY2018 | Sep 30, 2018 | $211.85K | -7.2% |
| FY2017 | Sep 30, 2017 | $228.29K | -82.0% |
| FY2016 | Sep 30, 2016 | $1.27M | +241.7% |
| FY2014 | Aug 31, 2014 | $372.13K | -31.8% |
| FY2013 | Aug 31, 2013 | $545.47K | +90.7% |
| FY2012 | Aug 31, 2012 | $286.05K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $0 | -100.0% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $0 | -100.0% |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | $0 | -100.0% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $0 | -100.0% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $500 | 0.0% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $109.99K | – |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $110.52K | – |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $107.80K | +98.7% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $500 | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $0 | -100.0% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $0 | -100.0% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $54.26K | +1783.9% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $0 | -100.0% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $64.05K | +1.6% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $20.49K | -85.6% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $2.88K | -99.0% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $20.53K | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $63.02K | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $141.86K | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $276.10K | – |
See a number that looks wrong?